Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis

Suad Abdeen, Samuel O Olusi, Sunila GeorgeDepartment of Pathology, Faculty of Medicine, Kuwait University, Safat, KuwaitBackground and aims: The hepatic stellate cell, which plays a pivotal role in hepatic fibrosis, contains the filament vimentin which is known to undergo protein citrullination and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Suad Abdeen, Samuel O Olusi, Sunila George
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/2692690770bc48ee8173f4cc2b2e6c58
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2692690770bc48ee8173f4cc2b2e6c58
record_format	dspace
spelling	oai:doaj.org-article:2692690770bc48ee8173f4cc2b2e6c582021-12-02T08:51:57ZSerum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis1179-1535https://doaj.org/article/2692690770bc48ee8173f4cc2b2e6c582011-03-01T00:00:00Zhttp://www.dovepress.com/serum-anti-modified-citrullinated-vimentin-antibody-concentration-is-a-a6631https://doaj.org/toc/1179-1535Suad Abdeen, Samuel O Olusi, Sunila GeorgeDepartment of Pathology, Faculty of Medicine, Kuwait University, Safat, KuwaitBackground and aims: The hepatic stellate cell, which plays a pivotal role in hepatic fibrosis, contains the filament vimentin which is known to undergo protein citrullination and become immunogenic. The aims of this study were to find out if anti-modified citrullinated vimentin (anti-MCV) antibodies are produced in patients with chronic hepatitis and if such production is associated with liver fibrosis.Methods: Sera and liver biopsy specimens were collected from 100 patients with chronic hepatitis. Sera were also collected from 100 healthy controls. The liver biopsies were graded according to the Metavir fibrosis scores. The serum concentrations of anti-MCV antibody were measured in both patients and controls by ELISA using commercially available kits.Results: The mean serum concentration of anti-MCV antibody in patients with chronic hepatitis (54.90 &plusmn; 6.09 U/mL) was significantly higher (P = 0.001) than that of controls (17.38 &plusmn; 0.56 U/mL). Furthermore, serum anti-MCV antibody titer was able to separate patients with no fibrosis from those with moderate or severe fibrosis or cirrhosis. Using receiver operating characteristic curves, a serum concentration of anti-MCV antibody of 8.82 U/mL was able to diagnose cirrhosis with 60% specificity and 60% sensitivity.Conclusion: We concluded that serum anti-MCV antibody concentration may be a sensitive noninvasive marker for liver cirrhosis that needs to be investigated further.Keywords: anti-MCV antibody, serum marker, liver fibrosis Suad AbdeenSamuel O OlusiSunila GeorgeDove Medical PressarticleDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2011, Iss default, Pp 13-18 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Suad Abdeen Samuel O Olusi Sunila George Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
description	Suad Abdeen, Samuel O Olusi, Sunila GeorgeDepartment of Pathology, Faculty of Medicine, Kuwait University, Safat, KuwaitBackground and aims: The hepatic stellate cell, which plays a pivotal role in hepatic fibrosis, contains the filament vimentin which is known to undergo protein citrullination and become immunogenic. The aims of this study were to find out if anti-modified citrullinated vimentin (anti-MCV) antibodies are produced in patients with chronic hepatitis and if such production is associated with liver fibrosis.Methods: Sera and liver biopsy specimens were collected from 100 patients with chronic hepatitis. Sera were also collected from 100 healthy controls. The liver biopsies were graded according to the Metavir fibrosis scores. The serum concentrations of anti-MCV antibody were measured in both patients and controls by ELISA using commercially available kits.Results: The mean serum concentration of anti-MCV antibody in patients with chronic hepatitis (54.90 &plusmn; 6.09 U/mL) was significantly higher (P = 0.001) than that of controls (17.38 &plusmn; 0.56 U/mL). Furthermore, serum anti-MCV antibody titer was able to separate patients with no fibrosis from those with moderate or severe fibrosis or cirrhosis. Using receiver operating characteristic curves, a serum concentration of anti-MCV antibody of 8.82 U/mL was able to diagnose cirrhosis with 60% specificity and 60% sensitivity.Conclusion: We concluded that serum anti-MCV antibody concentration may be a sensitive noninvasive marker for liver cirrhosis that needs to be investigated further.Keywords: anti-MCV antibody, serum marker, liver fibrosis
format	article
author	Suad Abdeen Samuel O Olusi Sunila George
author_facet	Suad Abdeen Samuel O Olusi Sunila George
author_sort	Suad Abdeen
title	Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
title_short	Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
title_full	Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
title_fullStr	Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
title_full_unstemmed	Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
title_sort	serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/2692690770bc48ee8173f4cc2b2e6c58
work_keys_str_mv	AT suadabdeen serumantimodifiedcitrullinatedvimentinantibodyconcentrationisassociatedwithliverfibrosisinpatientswithchronichepatitis AT samueloolusi serumantimodifiedcitrullinatedvimentinantibodyconcentrationisassociatedwithliverfibrosisinpatientswithchronichepatitis AT sunilageorge serumantimodifiedcitrullinatedvimentinantibodyconcentrationisassociatedwithliverfibrosisinpatientswithchronichepatitis
_version_	1718398353404854272

Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis

Ejemplares similares